Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma

Journal of Radiation Research

Volumn 53, Issue 2, 2012, Pages 202-210

  Koom, Woong Sub ^a   Park, Soo Yeon ^b   Kim, Wonwoo ^b   Kim, Minjung ^b   Kim, Ji Seong ^b   Kim, Hyunki ^c   Choi, Il Kyu ^d   Yun, Chae Ok ^b,d   Seong, Jinsil ^a  

^a Department of Radiation Oncology ^*  (South Korea)

^b Institute for Cancer Research   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

Adenovirus; Gene therapy; MDM2; P53; Radiotherapy

Indexed keywords

CELL CULTURE; CELL DEATH; GENE TRANSFER; RADIOTHERAPY; TUMORS;

ADENOVIRUS; ANTITUMOR EFFECT; CELL VIABILITY; ENHANCEMENT FACTOR; GROWTH ENHANCEMENT; HEPATOCELLULAR CARCINOMA; IN-VITRO; MDM2; P53 GENE; RADIATION-INDUCED;

GENE THERAPY;

ADENOVIRIDAE;

EID: 84863452345     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.11110     Document Type: Article

References (33)

1. Bruix J and Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
2. Bruix J and Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
3. Lawrence TS, et al (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31: 1237-1248.
4. Hawkins MA and Dawson LA (2006) Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106: 1653-1663.
5. Seong J (2009) Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J 50: 601-612.
6. Gerbes AL and Caselmann WH (1993) Point mutations of the P53 gene, human hepatocellular carcinoma and aflatoxins. J Hepatol 19:312-315.
7. Fei P and El-Deiry WS (2003) P53 and radiation responses. Oncogene 22: 5774-5783.
8. Picksley SM and Lane DP (1993) The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15: 689-690.
9. Chen J, Marechal V and Levine AJ (1993) Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13: 4107-4114.
10. Haupt Y, et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
11. Vazquez A, et al (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
12. Milas L, et al (1999) Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59: 107-114.
13. Nagasawa H, et al (1995) Relationship between radiationinduced Gl phase arrest and p53 function in human tumor cells. Cancer Res 55: 1842-1846.
14. Vousden KH and Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
15. Kastan MB, Canman CE and Leonard CJ (1995) P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 14: 3-15.
16. Kastan MB, et al (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311.
17. Roth J A, et al (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2: 985-991.
18. Gotoh A, et al (1997) Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and pl6CDKN4) in human prostate cancers. J Urol 158: 636-641.
19. Spitz FR, et al (1996) Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2: 1665-1671.
20. Li JH, et al (1999) The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 43: 607-616.
21. Badie B, et al (1999) Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther 6: 155-162.
22. Reifenberger G, et al (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739.
23. Wunder JS, et al (1999) Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 18: 783-788.
24. Barak Y, et al (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468.
25. Chen CY, et al (1994) Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91: 2684-2688.
26. Kussie PH, et al (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
27. Kubbutat MH, Jones SN and Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303.
28. Momand J, et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
29. Shangary S and Wang S (2008) Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14: 5318-5324.
30. Chene P (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109.
31. Sauthoff H, et al (2006) Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and Elb- 55kD-mediated degradation of p53. Cancer Gene Ther 13: 686-695.
32. Wang H, et al (2003) Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 1002:217-235.
33. Zhang Z, et al (2004) Radiosensitization by antisense anti- MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 10: 1263-1273.